At 31 December 2021, the equities held as part of fund assets are distributed as follows:
At 31 December 2021, the bonds held as part of fund assets are distributed as follows:
Around 76% of all these bonds are sovereign bonds, mainly issued by the United Kingdom. The balance mainly consists of bonds issued by financial and non- financial firms.
The portion of sovereign bonds issued by the United Kingdom was 5 percentage points higher than at 31 December 2020.
Cash flows related to future employee benefits are as follows:
(in millions of euros) | Cash flow underyear-end economic conditions | Amount covered by provisions (present value) |
---|---|---|
Less than one year |
Less than one year Cash flow underyear-end economic conditions428 |
Less than one year Amount covered by provisions (present value)416 |
One to five years |
One to five years Cash flow underyear-end economic conditions1,847 |
One to five years Amount covered by provisions (present value)1,769 |
Five to ten years |
Five to ten years Cash flow underyear-end economic conditions2,598 |
Five to ten years Amount covered by provisions (present value)2,289 |
More than ten years |
More than ten years Cash flow underyear-end economic conditions11,135 |
More than ten years Amount covered by provisions (present value)5,936 |
CASH FLOWS RELATED TO EMPLOYEE BENEFITS | CASH FLOWS RELATED TO EMPLOYEE BENEFITSCash flow underyear-end economic conditions16,008 | CASH FLOWS RELATED TO EMPLOYEE BENEFITSAmount covered by provisions (present value)10,410 |
The average weighted duration of funds in the United Kingdom is 23.3 years at 31 December 2021.
31/12/2021 | 31/12/2020 | ||||||
---|---|---|---|---|---|---|---|
(in millions of euros) | Notes | Current | Non-current | Total | Current | Non-current | Total |
Other provisions for decommissioning | 17.1 | 95 | 1,872 | 1,967 | 120 | 1 744 | 1 864 |
Other provisions | 17.2 | 3,245 | 3,570 | 6,815 | 2,675 | 3 630 | 6 305 |
OTHER PROVISIONS | 3,340 | 5,442 | 8,782 | 2,795 | 5 374 | 8 169 |
The breakdown by company is as follows:
(in millions of euros) | EDF | EDF Energy | Edison | Framatome | Other | Total |
---|---|---|---|---|---|---|
OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021EDF770 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021EDF Energy123 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021Edison188 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021Framatome443 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021Other443 | OTHER PROVISIONS FOR DECOMMISSIONING AT 31/12/2021Total1,967 |
Other provisions for decommissioning at 31/12/2020 |
Other provisions for decommissioning at 31/12/2020 EDF772 |
Other provisions for decommissioning at 31/12/2020 EDF Energy128 |
Other provisions for decommissioning at 31/12/2020 Edison172 |
Other provisions for decommissioning at 31/12/2020 Framatome412 |
Other provisions for decommissioning at 31/12/2020 Other380 |
Other provisions for decommissioning at 31/12/2020 Total1,864 |
Other provisions for decommissioning principally concern fossil-fired power plants, installations for the production of nuclear fuel assemblies, and dismantling of wind farms.
The costs of decommissioning fossil-fired power plants are calculated using regularly updated studies based on estimated future costs, measured by reference to the charges recorded on past operations and the most recent estimates for plants still in operation. The provision recorded at 31 December 2021 reflects the most recent known cost estimates and includes rehabilitation costs for generation sites.
Provisions for decommissioning notably include €161 million for Basic nuclear facilities (INB) in France, in the amounts of €97 million for Framatome and €64 million for Cyclife France. Dedicated assets have been set aside to cover these provisions as required by the regulations.
The dedicated assets of Framatome and Cyclife France (formerly SOCODEI) relating to Basic nuclear facilities (INB) in France have realisable values of €109 million in Framatome and €63 million in Cyclife France and the degree of coverage of provisions according to the regulations is 111% for Framatome and 98% for Cyclife France (by administrative prescription of 22 November 2021, Cyclife must by the 2022 year-end return to a coverage ratio of at least 100%).